Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Coherus Oncology (CHRS) Equity Average (2016 - 2025)

Coherus Oncology's Equity Average history spans 12 years, with the latest figure at $74.4 million for Q4 2025.

  • For Q4 2025, Equity Average rose 167.64% year-over-year to $74.4 million; the TTM value through Dec 2025 reached $74.4 million, up 167.64%, while the annual FY2025 figure was -$35.5 million, 78.19% up from the prior year.
  • Equity Average for Q4 2025 was $74.4 million at Coherus Oncology, down from $103.8 million in the prior quarter.
  • Across five years, Equity Average topped out at $204.3 million in Q1 2021 and bottomed at -$185.6 million in Q2 2023.
  • The 5-year median for Equity Average is -$71.4 million (2022), against an average of -$31.1 million.
  • The largest annual shift saw Equity Average crashed 3588.37% in 2023 before it surged 220.64% in 2025.
  • A 5-year view of Equity Average shows it stood at $114.2 million in 2021, then tumbled by 202.65% to -$117.3 million in 2022, then plummeted by 39.43% to -$163.5 million in 2023, then surged by 32.74% to -$110.0 million in 2024, then soared by 167.64% to $74.4 million in 2025.
  • Per Business Quant, the three most recent readings for CHRS's Equity Average are $74.4 million (Q4 2025), $103.8 million (Q3 2025), and -$31.8 million (Q2 2025).